|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
B Torok-Storb, K Doney, SL Brown and RL Prentice
Two in vitro tests were applied to 54 consecutive patients with severe
aplastic anemia who were treated in Seattle with antithymocyte globulin. In
the first test, peripheral blood mononuclear cells were collected from each
patient before antithymocyte globulin therapy and then treated with a panel
of monoclonal antibodies and complement. The treated peripheral blood
mononuclear cells were assayed for erythroid burst-forming units (BFU-E).
This test was designed to determine whether removing various subpopulations
of peripheral blood mononuclear cells would increase the number of
detectable BFU-E. In the second test, peripheral blood was collected within
48 hr after completion of antithymocyte globulin therapy, and cells were
immediately assayed for BFU-E without any further treatment. Data from both
tests were analyzed to determine whether the in vitro results correlated
with patient response to therapy. Binary logistic regression analyses
indicate that a modest correlation (p = 0.04) exists between test 1 in
vitro results and patient response to therapy. However, the strength of
this association appears to decrease as the interval between diagnosis and
treatment increases. In contrast, test 2 had a very significant correlation
(p = 0.001) with response to therapy among patients diagnosed more than 1
mo prior to treatment, whereas such an association was not apparent among
patients treated within 1 mo of diagnosis.
This article has been cited by other articles:
| ||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1984 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
